Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 440

1.

PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

Perrone F, Da Riva L, Orsenigo M, Losa M, Jocollè G, Millefanti C, Pastore E, Gronchi A, Pierotti MA, Pilotti S.

Neuro Oncol. 2009 Dec;11(6):725-36. doi: 10.1215/15228517-2009-003. Epub .

2.

Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.

Perrone F, Jocollè G, Pennati M, Deraco M, Baratti D, Brich S, Orsenigo M, Tarantino E, De Marco C, Bertan C, Cabras A, Bertulli R, Pierotti MA, Zaffaroni N, Pilotti S.

Eur J Cancer. 2010 Oct;46(15):2837-48. doi: 10.1016/j.ejca.2010.06.130. Epub 2010 Aug 6.

PMID:
20692828
3.

Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.

Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, Iida K, Matsumoto Y, Hakozaki M, Aoki M, Iwasaki H, Dobashi Y, Nishiyama K, Iwamoto Y, Oda Y.

Clin Cancer Res. 2013 Jan 15;19(2):450-61. doi: 10.1158/1078-0432.CCR-12-1067. Epub 2012 Dec 3.

4.
5.

EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.

Holtkamp N, Malzer E, Zietsch J, Okuducu AF, Mucha J, Mawrin C, Mautner VF, Schildhaus HU, von Deimling A.

Neuro Oncol. 2008 Dec;10(6):946-57. doi: 10.1215/15228517-2008-053. Epub 2008 Jul 23.

6.

Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.

Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, Rusch V, Ladanyi M.

J Thorac Oncol. 2011 May;6(5):864-74.

PMID:
21774103
7.

Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma.

Teng HW, Wang HW, Chen WM, Chao TC, Hsieh YY, Hsih CH, Tzeng CH, Chen PC, Yen CC.

J Surg Oncol. 2011 Jun;103(8):773-81. doi: 10.1002/jso.21852. Epub 2011 Jan 15.

PMID:
21240992
8.
10.

Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.

Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E, Gronchi A, Stacchiotti S, Manenti G, Casali PG, Pierotti MA, Pilotti S.

Neuro Oncol. 2010 Aug;12(8):776-89. doi: 10.1093/neuonc/noq003. Epub 2010 Feb 17.

11.

Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.

Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, Casali PG, Pilotti S.

Clin Cancer Res. 2006 Dec 1;12(23):6920-8.

12.

A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans.

Bongers G, Muniz LR, Pacer ME, Iuga AC, Thirunarayanan N, Slinger E, Smit MJ, Reddy EP, Mayer L, Furtado GC, Harpaz N, Lira SA.

Gastroenterology. 2012 Sep;143(3):730-40. doi: 10.1053/j.gastro.2012.05.034. Epub 2012 May 26.

13.

PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma.

Rodriguez EF, Scheithauer BW, Giannini C, Rynearson A, Cen L, Hoesley B, Gilmer-Flynn H, Sarkaria JN, Jenkins S, Long J, Rodriguez FJ.

Acta Neuropathol. 2011 Mar;121(3):407-20. doi: 10.1007/s00401-010-0784-9. Epub 2010 Nov 28.

14.

The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.

Zietsch J, Ziegenhagen N, Heppner FL, Reuss D, von Deimling A, Holtkamp N.

PLoS One. 2010 Jul 29;5(7):e11858. doi: 10.1371/journal.pone.0011858.

15.

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

Juanpere N, Agell L, Lorenzo M, de Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S.

Hum Pathol. 2012 Oct;43(10):1573-82. doi: 10.1016/j.humpath.2011.10.026. Epub 2012 Mar 12.

PMID:
22417847
16.

Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.

Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Góth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB.

Endocr Relat Cancer. 2009 Dec;16(4):1329-38. doi: 10.1677/ERC-09-0101. Epub 2009 Jul 20.

17.

EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.

Li T, Yang Y, Li X, Xu C, Meng L.

Mol Cell Biochem. 2012 Feb;361(1-2):19-29. doi: 10.1007/s11010-011-1082-0. Epub 2011 Sep 28.

PMID:
21952748
18.

Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors.

Dobashi Y, Suzuki S, Sugawara H, Ooi A.

Hum Pathol. 2007 Jun;38(6):914-25. Epub 2007 Mar 21.

PMID:
17376509
19.

Ligand-dependent activation of EGFR in follicular dendritic cells sarcoma is sustained by local production of cognate ligands.

Vermi W, Giurisato E, Lonardi S, Balzarini P, Rossi E, Medicina D, Bosisio D, Sozzani S, Pellegrini W, Doglioni C, Marchetti A, Rossi G, Pileri S, Facchetti F.

Clin Cancer Res. 2013 Sep 15;19(18):5027-38. doi: 10.1158/1078-0432.CCR-13-1275. Epub 2013 Jul 25.

20.

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM.

Oncotarget. 2012 Sep;3(9):954-87. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk